




HCQ 800 mg BID 7 days




HCQ 600mg BID 1 day + 200mg TID 6 days




HCQ 600mg BID 7 days




HCQ 600mg BID 2 days + 200mg TID 5 days




HCQ 400mg BID 7 days




HCQ 800mg BID 1 day + 400mg BID 6 days




HCQ 200mg BID 7 days



HCQ 800mg BID 2 day + 400mg BID 5 days



HCQ 200mg TID 10 days



HCQ 400mg BID 1 day + 200mg BID 4 days




Figure S2: (Left) Simulated population PK plasma profiles following different BID/TID regimens including 800 mg, 600 mg, 400 mg, and 200 mg BID for 7 days and 200 mg TID for 10 days. (Right) Simulated population PK plasma profiles following loading dose regimens including 800 mg BID for 1 or 2 days followed by 400 mg BID maintenance dosing, 600 mg BID for 1 or 2 days followed by 200 mg TID maintenance dosing, and 400 mg BID 1 day followed by 200 mg BID maintenance dosing. Apparent in vitro EC50's were adjusted to account for plasma protein binding.